Articles

Find an Article

Filter articles

Applied Filters

Showing 1 to 10 of 324 results

UK experimental use exemptions: part 1—the original

15-07-2021Sophie Topham

In the first of a four-part series, Sophie Topham of Marks & Clerk explores how experimental use provides life sciences products with essential relief from patent infringement

Got a patent, now where to validate?

EU22-03-2021Sarah Kostiuk-Smith

For smaller companies and universities, deciding where to validate a pharma patent can be difficult. Sarah Kostiuk-Smith of Mewburn Ellis looks at the options within the European Patent Convention countries.

Patent filing strategies for pharma startups

International16-03-2021Jian Siang Poh and Angus Fairbairn

Patents are a key asset for pharmaceutical startups, but where are they choosing to file? Jian Siang Poh and Angus Fairbairn of Marks & Clerk report.

The importance of Minerva Surgical v Hologic

US02-02-2021Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks

A decision by the Supreme Court over the assignor estoppel doctrine could have far-reaching implications for patent law, argue Jeffrey D Morton, Zachary Schroeder and Ryan D Ricks of Snell & Wilmer.

What 2020 means for the life sciences

International, UK15-12-2020Sally Shorthose and Rumana Khanom

Between Brexit and COVID-19, 2020 has had seismic implications for the life sciences industries. Sally Shorthose and Rumana Khanom of Bird & Bird report.

Pricing, patents and the PMPRB in Canada

Canada14-12-2020Micheline Gravelle and Iris Cheung

Micheline Gravelle and Iris Cheung of Bereskin & Parr provide an update on the final version of guidelines issued by Canada’s federal drug price regulator—and its likely implications.

The doctrine of equivalents in the medtech arena

US18-11-2020Christopher Bright and Nathan Smith

The role of the doctrine of equivalents in assessing the value of, and risks associated with, medtech patents is often overlooked. Christopher Bright and Nathan Smith of Morgan Lewis report.

Why Santen ends Neurim-style SPCs

EU25-08-2020Robert Stephen and Gareth Morgan

In a boost for generic pharma companies, a U-turn by the EU’s highest court removed protection for repurposed active substances, as Robert Stephen and Gareth Morgan of CMS Cameron McKenna Nabarro Olswang explain.

The right recipe for the repurposing omelette

EU14-08-2020BiosimilarsJakob Wested and John Liddicoat

Big Pharma is looking for solutions to the COVID-19 pandemic wherever it can find them, so drug repurposing is more important than ever, as research lawyers Jakob Wested and John Liddicoat argue.

No SPC crown for Royalty Pharma

Germany10-07-2020Joel Beevers and Michael Pears

An attempt to obtain a supplementary protection certificate ended up raising the bar to achieving this coveted IP, as Joel Beevers and Michael Pears of Potter Clarkson explain.

Showing 1 to 10 of 324 results

LSIPR